For generations, type 1 diabetes has demanded daily surrender — insulin injections, blood sugar vigils, a lifelong negotiation with a body turned against itself. Now a Melbourne biotech born from Monash University is pursuing a quieter revolution: not managing the disease, but reasoning with the immune system that drives it. ImmunoBiota Therapeutics is seeking $5 million to carry its oral compound IBT-100 into pediatric trials, wagering that the gut holds a key to retraining the body's misdirected defenses before they do a lifetime of damage.
Immunobiota seeks $5M to advance oral diabetes treatment toward clinical trials
Type 1 diabetes affects millions globally who require lifelong insulin management; this treatment targets the underlying autoimmune mechanism rather than symptom management.